Cargando…

From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid

I(125) radioimmunoassay (RIA) is currently the standard technique for quantifying cerebrospinal fluid (CSF) orexin-A/hypocretin-1, a biomarker used to diagnose narcolepsy type 1. However, orexin-A RIA is liable to undergo cross-reactions with matrix constituents generating interference, high variabi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirtz, Christophe, Vialaret, Jérôme, Gabelle, Audrey, Nowak, Nora, Dauvilliers, Yves, Lehmann, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863245/ https://www.ncbi.nlm.nih.gov/pubmed/27165941 http://dx.doi.org/10.1038/srep25162

Ejemplares similares

Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy
por: Dauvilliers, Yves A., et al.
Publicado: (2014)

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry
por: Bros, Pauline, et al.
Publicado: (2015)

Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification
por: van der Hoeven, Adrienne Elisabeth, et al.
Publicado: (2022)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy
por: Lopez, Régis, et al.
Publicado: (2017)

Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
por: Hirtz, Christophe, et al.
Publicado: (2023)

Editorial: Hypocretins/Orexins
por: López, Miguel, et al.
Publicado: (2020)

Cerebrospinal Fluid Hypocretin-1 (Orexin-A) Level Fluctuates with Season and Correlates with Day Length
por: Boddum, Kim, et al.
Publicado: (2016)

Hypocretin (orexin) cell loss in Parkinson’s disease
por: Thannickal, Thomas C., et al.
Publicado: (2007)

Cerebrospinal Fluid Melanin-Concentrating Hormone (MCH) and Hypocretin-1 (HCRT-1, Orexin-A) in Alzheimer’s Disease
por: Schmidt, Frank M., et al.
Publicado: (2013)

Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness
por: Omori, Yuki, et al.
Publicado: (2018)

Decreased Cerebrospinal Fluid Orexin-A (Hypocretin-1) Concentrations in Patients after Generalized Convulsive Status Epilepticus
por: Samzadeh, Mojdeh, et al.
Publicado: (2020)

Correction: Cerebrospinal Fluid Melanin-Concentrating Hormone (MCH) and Hypocretin-1 (HCRT-1, Orexin-A) in Alzheimer’s Disease
por: Schmidt, Frank M., et al.
Publicado: (2013)

Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness [Corrigendum]
Publicado: (2018)

Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes
por: Trotti, Lynn Marie, et al.
Publicado: (2021)

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

IGFBP3 Colocalizes with and Regulates Hypocretin (Orexin)
por: Honda, Makoto, et al.
Publicado: (2009)

Hypocretin (orexin) regulation of sleep-to-wake transitions
por: de Lecea, Luis, et al.
Publicado: (2014)

Sexually Dimorphic Changes of Hypocretin (Orexin) in Depression
por: Lu, Jing, et al.
Publicado: (2017)

Orexins/Hypocretins: Key Regulators of Energy Homeostasis
por: Milbank, Edward, et al.
Publicado: (2019)

Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson’s disease
por: Thannickal, Thomas C., et al.
Publicado: (2008)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Circadian and dark-pulse activation of orexin/hypocretin neurons
por: Marston, Oliver J, et al.
Publicado: (2008)

Early Expression of Hypocretin/Orexin in the Chick Embryo Brain
por: Godden, Kyle E., et al.
Publicado: (2014)

THE REGULATION OF SLEEP AND WAKEFULNESS BY THE HYPOTHALAMIC NEUROPEPTIDE OREXIN/HYPOCRETIN
por: INUTSUKA, AYUMU, et al.
Publicado: (2013)

Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target
por: Alain, Couvineau, et al.
Publicado: (2021)

Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches
por: Vialaret, Jerome, et al.
Publicado: (2018)

Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Self-Administration Is Mediated Predominantly by Hypocretin Receptor 1
por: Prince, Courtney D., et al.
Publicado: (2014)

Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
por: Mohaupt, Pablo, et al.
Publicado: (2023)

OX(1) and OX(2) orexin/hypocretin receptor pharmacogenetics
por: Thompson, Miles D., et al.
Publicado: (2014)

Involvement of PLAGL1/ZAC1 in hypocretin/orexin transcription
por: Tanaka, Susumu, et al.
Publicado: (2019)

Hypocretin/orexin influences chronic sleep disruption injury in the hippocampus
por: Nick, Henry, et al.
Publicado: (2022)

Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity
por: Turku, Ainoleena, et al.
Publicado: (2017)

Hepcidin and ferritin levels in restless legs syndrome: a case–control study
por: Chenini, Sofiene, et al.
Publicado: (2020)

Hypocretin/orexin regulation of dopamine signaling: implications for reward and reinforcement mechanisms
por: Calipari, Erin S., et al.
Publicado: (2012)

The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship
por: Kim, Andrezza K., et al.
Publicado: (2012)

The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress
por: Chow, Matthew, et al.
Publicado: (2016)

The integrative role of orexin/hypocretin neurons in nociceptive perception and analgesic regulation
por: Inutsuka, Ayumu, et al.
Publicado: (2016)

Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation
por: Nevárez, Natalie, et al.
Publicado: (2018)

Physiological Implications of Orexins/Hypocretins on Energy Metabolism and Adipose Tissue Development
por: Liu, Lingbin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hkak5pd37e1oh316vp90b0lhrn